Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Invion ( (AU:IVX) ) is now available.
Invion Limited has addressed a query from the ASX regarding the timing of its cleansing notice related to its Phase I/II trial for non-melanoma skin cancer. The company confirmed that the trial showed no adverse events and that the treatment was well tolerated with observable reductions in lesion size, marking a significant advancement over existing PDT treatments. This development is crucial for Invion’s market positioning as it demonstrates the potential efficacy and safety of its treatment, which could enhance investor confidence and stakeholder interest.
More about Invion
Invion Limited operates in the biotechnology industry, focusing on the development of Photodynamic Therapy (PDT) treatments for non-melanoma skin cancer (NMSC). The company is engaged in clinical trials to advance its therapeutic solutions in this niche market.
Average Trading Volume: 102,006
Technical Sentiment Signal: Sell
Current Market Cap: A$10.17M
See more data about IVX stock on TipRanks’ Stock Analysis page.